# Zhejiang Jiuzhou Pharmaceutical Co., Ltd., Taizhou, China – FDA Inspections

Source: https://www.keypedia.com/companies/zhejiang-jiuzhou-pharmaceutical-co-ltd/6ff21ff3-4c18-4e07-9c38-79e499bfb8fa

> Inspection records and compliance data for Zhejiang Jiuzhou Pharmaceutical Co., Ltd. in Taizhou. 5 FDA inspections on record (1 OAI), 1 Form 483, 1 warning letter, last inspected August 23, 2024.

---

## Details

- Name: Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
- FEI Number: 3003744377
- Business Operations: API MANUFACTURE
- Address Line 1: NO. 99 Waishalu, Jiaojiang
- City: Taizhou
- Country Name: China
- Address: NO. 99 Waishalu, Jiaojiang, Taizhou, China
- Country: China

## Related Documents

- [FDA Inspection 1249624 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2024-08-23](https://www.keypedia.com/records/fda_inspections/zhejiang-jiuzhou-pharmaceutical-co-ltd/99b888b3-e8d0-42b9-b6f8-b62cae24033b) — classification: No Action Indicated (NAI), source: FDA, date: August 23, 2024
- FDA Inspection 1249624 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2024-08-23 — classification: No Action Indicated (NAI), source: FDA, date: August 23, 2024
- [FDA Inspection 1068522 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2018-09-13](https://www.keypedia.com/records/fda_inspections/zhejiang-jiuzhou-pharmaceutical-co-ltd/9cb872c0-80e9-4fe9-bf78-512755f7304d) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 13, 2018
- FDA Inspection 1068522 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2018-09-13 — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 13, 2018
- [483 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2018-09-10](https://www.keypedia.com/records/483/zhejiang-jiuzhou-pharmaceutical-co-ltd/7f901124-3391-440f-b3ab-e7f6a1b7af7d) — source: FDA, date: September 10, 2018
- FDA Inspection 957458 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2016-01-23 — classification: Voluntary Action Indicated (VAI), source: FDA, date: January 23, 2016
- [FDA Inspection 957458 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2016-01-23](https://www.keypedia.com/records/fda_inspections/zhejiang-jiuzhou-pharmaceutical-co-ltd/cc0eea86-f35f-406c-a69a-c35c8bc52732) — classification: Voluntary Action Indicated (VAI), source: FDA, date: January 23, 2016
- [WARNING_LETTER - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2013-10-24](https://www.keypedia.com/records/warning_letter/zhejiang-jiuzhou-pharmaceutical-co-ltd/d6aee00f-a341-4a32-8adc-33ae5b663aa6) — source: FDA, date: October 24, 2013
- FDA Inspection 853880 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2013-10-24 — classification: Official Action Indicated (OAI), source: FDA, date: October 24, 2013
- [FDA Inspection 853880 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2013-10-24](https://www.keypedia.com/records/fda_inspections/zhejiang-jiuzhou-pharmaceutical-co-ltd/f3e2cf30-bf8b-440f-a309-30dcd1bb8157) — classification: Official Action Indicated (OAI), source: FDA, date: October 24, 2013
- FDA Inspection 729378 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2011-04-21 — classification: Voluntary Action Indicated (VAI), source: FDA, date: April 21, 2011
- [FDA Inspection 729378 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. - 2011-04-21](https://www.keypedia.com/records/fda_inspections/zhejiang-jiuzhou-pharmaceutical-co-ltd/f3834992-8a45-4481-9757-41d4af7e78f0) — classification: Voluntary Action Indicated (VAI), source: FDA, date: April 21, 2011

## Related Companies

- [Bachem Americas, Inc.](https://www.keypedia.com/companies/bachem-americas-inc/3a9656ad-737b-4682-9ab3-951b1041002e)
- [PolyPeptide Laboratories, Inc.](https://www.keypedia.com/companies/polypeptide-laboratories-inc/9d05664c-4a42-45cc-81f6-ef85c356ecc1)
- [Shandong Xinhua Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/shandong-xinhua-pharmaceutical-co-ltd/acea3619-5739-4a9f-a4b2-82e0207194b3)
- [Livzon Group (Ningxia) Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/livzon-group-ningxia-pharmaceutical-co-ltd/78a1f9d4-41d0-440a-87bc-8c9521d0159a)
- [Novacyl](https://www.keypedia.com/companies/novacyl/928b015a-ee45-4383-ad21-070b43308727)
- [Livzon New North River Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/livzon-new-north-river-pharmaceutical-co-ltd/49cdcdc8-9c6c-4486-b6cd-e404c21dd2d2)
- [BioSpectra, Inc.](https://www.keypedia.com/companies/biospectra-inc/ffb13a38-4f04-49cb-a6fe-fd55f544fcf0)
- [Dottikon Exclusive Synthesis AG](https://www.keypedia.com/companies/dottikon-exclusive-synthesis-ag/db7bdf8b-bd88-416f-94f2-62f946e90074)
- [Cosma SPA](https://www.keypedia.com/companies/cosma-spa/14f96eaf-912e-4eed-af27-43ec40d9b7b7)
- [Siegfried (Nantong) Pharmaceuticals Co., Ltd.](https://www.keypedia.com/companies/siegfried-nantong-pharmaceuticals-co-ltd/0f735555-bd37-452f-b5f5-a205454957c1)

## Related Officers

- [Director - Division of Compliance](https://www.keypedia.com/people/eric-m-nelson/301ef659-ae6a-41c5-9a3e-9cfbc0369670)
- [Thomas J. Cosgrove](https://www.keypedia.com/people/thomas-j-cosgrove/616abec3-5ed9-42aa-9f5d-392b5552b695)
- [ Investigator ](https://www.keypedia.com/people/matthew-b-casale/e78481c6-5fbd-4723-a79c-167176395af8)
- [President](https://www.keypedia.com/people/zhi-hong-chen/875a5274-0bf2-47da-9739-030f1ebc0575)
